PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
Ronan J. Kelly, MD, MBA & Daniela Molena, MD - Immunotherapy at the Cutting Edge in Resectable Esophageal/GEJ Cancer: Preparing Thoracic Surgeons and the Broader Multidisciplinary Team to Navigate Changing Standards of Care
Go online to PeerView.com/KZR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you integrating the latest optimal treatments into the management plans for your patients with esophageal/gastroesophageal junction (GEJ) cancer? The approval of the PD-1 inhibitor nivolumab in the adjuvant setting has provided a new opportunity for patients to achieve longer disease-free survival, a goal that had not been attainable with conventional modalities. Despite guideline recommendations and clinical evidence demonstrating the role of immunotherapy in esophageal/GEJ cancer, many eligible patients are not receiving this game-changing treatment, and patients in other settings are not being enrolled in clinical trials of immune checkpoint inhibitors. By combining in-depth discussions on the latest data and key clinical issues with expert guidance on integrating immunotherapy into multimodal practice, PeerView’s Candid Conversations & Clinical Consults event is designed to help clinicians incorporate new standards of care into the treatment of their patients with esophageal/GEJ cancer. Don’t miss this opportunity to learn how thoracic surgeons, oncologists, and other oncology team members can collaborate to bring practice-changing science into the clinic. Upon completion of this CE activity, participants will be able to: Identify appropriate patients with resectable esophageal/GEJ cancer who are candidates for adjuvant therapy with an immune checkpoint inhibitor, Apply multimodal treatment protocols for locally advanced or earlier-stage esophageal/GEJ cancer to incorporate novel immunotherapy options for eligible patients, either in the context of clinical practice or through clinical trial participation, based on the latest evidence, indications, guideline recommendations, and patient-centered factors, Collaborate with the broader multidisciplinary team to optimally integrate novel immunotherapy options into individualized treatment plans, including strategies to promptly recognize and manage potential immune-related adverse events, for patients with locally advanced or early-stage esophageal/GEJ cancer.